Literature DB >> 34593069

Regional outbreak of multidrug-resistant Klebsiella pneumoniae carbapenemase-producing Pseudomonas Aeruginosa.

Bekana K Tadese1,2, Anna Nutt3, Ifrah Chaudhary4, Charlene Offiong4, Charles Darkoh2,5.   

Abstract

Klebsiella pneumoniae carbapenemase-producing P. aeruginosa (KPC-CRPA) are rare in the United States. An outbreak of KPC-CRPA was investigated in Texas using molecular and epidemiologic methods and 17 cases of KPC-CRPA were identified. The isolates were genetically related and harbored the emerging P. aeruginosa multilocus sequence type 235, the first in the United States.

Entities:  

Year:  2021        PMID： 34593069      PMCID： PMC8971143          DOI： 10.1017/ice.2021.394

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN： 0899-823X            Impact factor:   3.254


  9 in total

1.  Emergence of KPC-producing Pseudomonas aeruginosa in the United States.

Authors:  Laurent Poirel; Patrice Nordmann; Emilie Lagrutta; Timothy Cleary; L Silvia Munoz-Price
Journal:  Antimicrob Agents Chemother       Date:  2010-04-26       Impact factor: 5.191

2.  First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.

Authors:  Maria Virginia Villegas; Karen Lolans; Adriana Correa; Juan Nicolas Kattan; Jaime A Lopez; John P Quinn
Journal:  Antimicrob Agents Chemother       Date:  2007-01-29       Impact factor: 5.191

3.  Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections.

Authors:  D Ben-David; R Kordevani; N Keller; I Tal; A Marzel; O Gal-Mor; Y Maor; G Rahav
Journal:  Clin Microbiol Infect       Date:  2011-07-01       Impact factor: 8.067

4.  Emergence and rapid regional spread of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae.

Authors:  Sarah Y Won; L Silvia Munoz-Price; Karen Lolans; Bala Hota; Robert A Weinstein; Mary K Hayden
Journal:  Clin Infect Dis       Date:  2011-09       Impact factor: 9.079

5.  Increased Mortality Among Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Carriers Who Developed Clinical Isolates of Another Genotype.

Authors:  Wen Kai Chen; Yong Yang; Ban Hock Tan
Journal:  Open Forum Infect Dis       Date:  2019-02-01       Impact factor: 3.835

6.  Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system.

Authors:  Andrea Endimiani; John M Depasquale; Sandra Forero; Federico Perez; Andrea M Hujer; Daneshia Roberts-Pollack; Paul D Fiorella; Nancy Pickens; Brandon Kitchel; Aida E Casiano-Colón; Fred C Tenover; Robert A Bonomo
Journal:  J Antimicrob Chemother       Date:  2009-09-09       Impact factor: 5.790

7.  blaVIM-7, an evolutionarily distinct metallo-beta-lactamase gene in a Pseudomonas aeruginosa isolate from the United States.

Authors:  Mark A Toleman; Kenneth Rolston; Ronald N Jones; Timothy R Walsh
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

8.  Carbapenem-Resistant Pseudomonas aeruginosa at US Emerging Infections Program Sites, 2015.

Authors:  Maroya Spalding Walters; Julian E Grass; Sandra N Bulens; Emily B Hancock; Erin C Phipps; Daniel Muleta; Jackie Mounsey; Marion A Kainer; Cathleen Concannon; Ghinwa Dumyati; Chris Bower; Jesse Jacob; P Maureen Cassidy; Zintars Beldavs; Karissa Culbreath; Walter E Phillips; Dwight J Hardy; Roberto L Vargas; Margret Oethinger; Uzma Ansari; Richard Stanton; Valerie Albrecht; Alison Laufer Halpin; Maria Karlsson; J Kamile Rasheed; Alexander Kallen
Journal:  Emerg Infect Dis       Date:  2019-07       Impact factor: 6.883

9.  Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention and Control.

Authors:  A P Magiorakos; K Burns; J Rodríguez Baño; M Borg; G Daikos; U Dumpis; J C Lucet; M L Moro; E Tacconelli; G Skov Simonsen; E Szilágyi; A Voss; J T Weber
Journal:  Antimicrob Resist Infect Control       Date:  2017-11-15       Impact factor: 4.887
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.